Multiple Myeloma

Multiple myeloma—a cancer that forms in a type of blood cell called a plasma cell—is a chronic disease that requires ongoing care and monitoring. Our team of specialists partners with you throughout diagnosis and treatment. We use sophisticated diagnostic and genetic tests, some of which were developed at NYU Langone, to guide treatment planning. We also draw upon recent medical advances to provide you with customized therapy. Our doctors have conducted clinical trials to help establish a number of the medications in use today, including immune therapies and targeted medications.

Clinical Trials and Research Studies

Phase 5

A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma

Learn More

Phase 1

A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)

Learn More

Phase 1

An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease

Learn More

Phase 5

A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS

Learn More